Neuromelanin Magnetic Resonance Imaging in Parkinson's Disease and Multiple System Atrophy

Pigmented neurons in the substantia nigra pars compacta (SNc) and locus coeruleus (LC) show decreased numbers differentially in Parkinson's disease (PD) and multiple system atrophy (MSA). Recent reports have described that fast spin-echo T1-weighted magnetic resonance imaging (MRI) by a 3-tesla machine can visualize neuromelanin-related contrast of the noradrenergic and dopaminergic neurons respectively in the LC and the SNc. Using neuromelanin MRI at 3 T, we investigated possible alterations of these catecholaminergic neurons in 32 PD and 9 MSA patients, and compared the results with those of 23 normal volunteers. The contrast ratio of the LC and SNc was decreased in MSA and PD patients, most prominently in the LC in MSA patients. The contrast ratio of the SNc was correlated with the Hoehn-Yahr stage of PD and the severity of neuroradiological abnormalities in MSA. These results indicate a potential diagnostic value of neuromelanin MRI to distinguish MSA patients from normal and PD patients.

[1]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[2]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[3]  J. Greenfield,et al.  THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.

[4]  Francesco Federico,et al.  Proton magnetic resonance spectroscopy in parkinson's disease and atypical parkinsonian disorders , 1997 .

[5]  Paul M. Matthews,et al.  MRI characteristics of the substantia nigra in Parkinson's disease: A combined quantitative T1 and DTI study , 2009, NeuroImage.

[6]  K. Kashihara,et al.  Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. , 2011, Internal medicine.

[7]  J. Yun,et al.  Putaminal abnormality on 3-T magnetic resonance imaging in early parkinsonism-predominant multiple system atrophy , 2010, Journal of Neurology.

[8]  K. Kashihara,et al.  Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson’s disease , 2011, Journal of Clinical Neuroscience.

[9]  Klaus Seppi,et al.  Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. , 2010, Neuroimaging clinics of North America.

[10]  A J Lees,et al.  Clinical usefulness of magnetic resonance imaging in multiple system atrophy , 1998, Journal of neurology, neurosurgery, and psychiatry.

[11]  Yasuo Terayama,et al.  Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease , 2006, Neuroreport.

[12]  Dorothee P Auer,et al.  T1‐Weighted MRI shows stage‐dependent substantia nigra signal loss in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[13]  J. Parisi,et al.  Loss of A5 noradrenergic neurons in multiple system atrophy , 2008, Acta Neuropathologica.

[14]  F. Tison,et al.  Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD , 2003, Journal of Neural Transmission.

[15]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[16]  P. Yates,et al.  PATHOLOGICAL BASIS FOR NEUROTRANSMITTER CHANGES IN PARKINSON'S DISEASE , 1983, Neuropathology and applied neurobiology.

[17]  C. Marsden,et al.  Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy , 1995, Annals of neurology.

[18]  Chandrasekharan Kesavadas,et al.  Utility of susceptibility-weighted MRI in differentiating Parkinson’s disease and atypical parkinsonism , 2010, Neuroradiology.

[19]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[20]  Susan M. Resnick,et al.  Morphometry of the human substantia nigra in ageing and Parkinson’s disease , 2008, Acta Neuropathologica.

[21]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[22]  G. Fenichel,et al.  Studies on neuromelanin , 1967, Neurology.

[23]  Niall P Quinn,et al.  The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. , 2004, Brain : a journal of neurology.

[24]  Francesco Fera,et al.  Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. , 2006, Brain : a journal of neurology.

[25]  Francesco Fera,et al.  MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from Parkinson disease. , 2006, Radiology.

[26]  C Kremser,et al.  Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD , 2002, Neurology.

[27]  Y. Miki,et al.  "Hot cross bun" sign in multiple system atrophy with predominant cerebellar ataxia: a comparison between proton density-weighted imaging and T2-weighted imaging. , 2012, European journal of radiology.

[28]  N P Quinn,et al.  Clinicopathological study of 35 cases of multiple system atrophy. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[29]  F. Tison,et al.  Oral zolmitriptan is effective in the acute treatment of cluster headache , 2000, Neurology.

[30]  C. Good,et al.  Differentiation of atypical parkinsonian syndromes with routine MRI , 2000, Neurology.

[31]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[32]  D. Graham.  On the origin and significance of neuromelanin. , 1979, Archives of pathology & laboratory medicine.